

27.6.2022

SSG Board meeting

Time 3.6.2022 10.00-10.50 (11-11.50 Finnish Time)

Place Teams-meeting

Participants Christina Linder Stragliotto, Kaisa Sunela, Eva-Mari Olofsson, Panagiotis Tsagkozis, Katrin Maria Pulverer, Christina Berger, Lotta Våde

Subject	Decision
1 Opening of the meeting	Chairman Christina Linder Stragliotto opened the meeting.
2 Meeting secretary	Kaisa Sunela.
3 Introduction	Short introduction of the board members: Christina Linder Stragliotto is a medical oncologist in Sweden, Kaisa Sunela is a medical oncologist in Tampere, Finland. Christina Berger is an orthopedic surgeon in Gothenburg, Sweden, Kathrin Maria Pulverer is an orthopedic surgeon in Bergen, Norway. Lotta Våde is a nurse from Oslo, Norway (not in clinical position now, also in the previous board), Panagiotis Tsagkozis is an orthopedic surgeon in Stockholm, Sweden and was also in the previous board.
4 Financial situation	SSG XXII will get some money in, but the situation could be better. A member fee was in discussion, no decisions about this yet. About 150 000 SEK in the bank.
5 How do we want SSG to work in the future? Organization, home page, economy, future studies, educational activities, registries.	<p>Mostly well working organization. However, research could be stronger. Nurses should be included in the studies more. Kaisa tries to activate Finnish people to participate more in the SSG actions. Malmö working group meetings will continue yearly. E-mail lists should be updated. A member fee could be possible in the near future, but something more should be offered for members. Ideas of this were: exchange programs 1-2 weeks in other country, study grants, newsletters, participation in other congresses/sarcoma groups.</p> <p>Home page will be updated, for example photo of the board, an updated list of members, introduction of members and publications. Economy needs support, a member fee and collaborating studies with companies can be solutions.</p> <p>Pereli-1 phase II study (Lund and Oslo main responsible sites) with pemigatinib and PD-L1-antibody for dedifferentiated liposarcoma with Incyte's sponsorship should open in 1-1,5 years. SSGXXII study needs 14 more patients. SSGXX is in follow-up phase, but ongoing.</p> <p>We don't collect any data to the SSG central registry since nearly 7 years back. The data has been transferred to INCA</p>

Subject		Decision
		which now function as the Swedish Quality Register and all data is reported to this platform. Emelie Styring (chair of the SSG Orthopedic subcommittee, will be invited to the next board meeting and talk more about this.
6	Working group meeting in Malmö 5.-6.12.2022	Chairman will contact the working group leaders to have suggestions for subjects and to plan the program. There should be specialty specific subjects, but also main lectures for all. Ideas can be sent to chairman. Some subjects mentioned: update of studies, Ewing sarcoma (Martin McCabe to be invited to speak about HD-ifosphamide in relapsed disease, will be published in ASCO), immuno oncology, QoL, case reports. Timetable could be little shorter than in previous meetings, dinner in 7 p.m.?
7	Follow up of the Tampere meeting	Still some work to do, Christina will contact Kaisa, if needed. Finnish speakers were not happy when any of the work was not compensated. This could be improved with member fees. Also, instructions for the next meeting organizers should be clearer.
8	Next meeting	In the late August/early September. A Doodle with date suggestions will be sent out.